The estimated Net Worth of Russell H Ellison is at least $755 Mille dollars as of 14 May 2020. Dr Ellison owns over 2,000 units of Rockwell Medical Inc stock worth over $49,405 and over the last 15 years he sold RMTI stock worth over $0. In addition, he makes $705,918 as Pres e CEO & Director at Rockwell Medical Inc.
Dr has made over 1 trades of the Rockwell Medical Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of RMTI stock worth $4,160 on 14 May 2020.
The largest trade he's ever made was buying 2,000 units of Rockwell Medical Inc stock on 14 May 2020 worth over $4,160. On average, Dr trades about 400 units every 0 days since 2010. As of 14 May 2020 he still owns at least 12,050 units of Rockwell Medical Inc stock.
You can see the complete history of Dr Ellison stock trades at the bottom of the page.
Dr. Russell H. Ellison M.Sc., M.D., MSc. is the Pres, CEO & Director at Rockwell Medical Inc.
As the Pres e CEO & Director of Rockwell Medical Inc, the total compensation of Dr MSc at Rockwell Medical Inc is $705,918. There are 2 executives at Rockwell Medical Inc getting paid more, with Raymond Pratt having the highest compensation of $965,874.
Dr MSc is 73, he's been the Pres e CEO & Director of Rockwell Medical Inc since . There are no older and 16 younger executives at Rockwell Medical Inc.
Russell's mailing address filed with the SEC is C/O ROCKWELL MEDICAL, INC., 30142 S. WIXOM ROAD, WIXOM, MI, 48393.
Over the last 21 years, insiders at Rockwell Medical Inc have traded over $3,082,721 worth of Rockwell Medical Inc stock and bought 689,891 units worth $3,959,861 . The most active insiders traders include Robert L Chioini, David S.Rbi Private Investm... e Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of $170,433. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth $43,724.
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
Rockwell Medical Inc executives and other stock owners filed with the SEC include: